Stocktoria
CytomX Therapeutics, Inc. CTMX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-08
CytomX Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -29.3% | 18.1% | -6.4% | -190.6% | -311.0% |
| Net margin | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% |
| FCF margin | -99.5% | -62.7% | -56.2% | -211.7% | -323.3% |
| Return on assets | -11.5% | 26.4% | -0.3% | -38.1% | -34.1% |
| Return on equity | -17.5% | -6988.8% | 1.2% | 115.8% | 25244.0% |
| Current ratio | 3.09 | 1.25 | 1.17 | 1.55 | 3.98 |
| Revenue growth | -44.8% | 36.4% | 90.4% | 42.5% | -62.8% |
Source: SEC EDGAR filings · CIK 0001501989 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.